Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zahid Rafiq

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Journal of Experimental & Clinical Cancer Research : CR|September 1, 2024
Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapyKewen He, Nahum Puebla-Osorio, Hampartsoum B Barsoumian, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 5, 2024
Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapyYun Hu, Alexey Revenko, Hampartsoum Barsoumian, et al.
Journal of Medicinal Chemistry|January 14, 2025
Design and Synthesis of Topoisomerases-Histone Deacetylase Dual Targeted Quinoline-Bridged Hydroxamates as Anticancer AgentsGaurav Joshi, Umesh Prasad Yadav, Zahid Rafiq, et al.
Frontiers in Oncology|October 24, 2024
Enhanced tumor control and survival in preclinical models with adoptive cell therapy preceded by low-dose radiotherapyNahum Puebla-Osorio, Natalie Wall Fowlkes, Hampartsoum B Barsoumian, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Journal of Experimental & Clinical Cancer Research : CR|September 1, 2024
Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapyKewen He, Nahum Puebla-Osorio, Hampartsoum B Barsoumian, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 5, 2024
Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapyYun Hu, Alexey Revenko, Hampartsoum Barsoumian, et al.
Journal of Medicinal Chemistry|January 14, 2025
Design and Synthesis of Topoisomerases-Histone Deacetylase Dual Targeted Quinoline-Bridged Hydroxamates as Anticancer AgentsGaurav Joshi, Umesh Prasad Yadav, Zahid Rafiq, et al.
Frontiers in Oncology|October 24, 2024
Enhanced tumor control and survival in preclinical models with adoptive cell therapy preceded by low-dose radiotherapyNahum Puebla-Osorio, Natalie Wall Fowlkes, Hampartsoum B Barsoumian, et al.
Pageof 2